Answers are grounded in this paper and cite their sources.
Correction notes an updated dosing amount in a phase 1 trial targeting solid tumors, indicating accuracy in reporting.
In the version of the article initially published, in the “Phase 1a dose escalation” column in Fig. 2, the fifth dose was listed as “0.054 mg” but should have been “0.54 mg”. This correction has been made to the HTML and PDF versions of the article.
No takes yet. Share an insight, caveat, or question.
Wermke et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: